Johana Fajardo
Adult Health · Charleston, SCNPI 1043578438
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alnylam Pharmaceuticals Inc. accounts for 72.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $3,303 and has fallen 94.2% since, to $191 in 2025.
Across 31 payments — averaging $170.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$4K
- Akcea Therapeutics, Inc.$680
- Merck$220
- Bridgebio Pharma, Inc.$147
- Abbott$121
- Pfizer$68
- plus $221 from 6 others
What the payments were for
- Consulting fees$68013%
- Speaking & faculty fees$2,02538%
- Travel & lodging$1,00919%
- Food & beverage$1,57430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 14 | $3,829 |
| Akcea Therapeutics, Inc. | 1 | $680 |
| Merck | 2 | $220 |
| Bridgebio Pharma, Inc. | 1 | $147 |
| Abbott | 5 | $121 |
| Pfizer | 2 | $68 |
| E.r. Squibb & Sons, L.L.C. | 1 | $67 |
| Johnson & Johnson | 1 | $50 |
| Biosense Webster, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,288 in reported general payments places this provider in the 85th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 242 | $5,358,954 |
| VyndaqelTafamidis Meglumine | 11 | $168,904 |
| JardianceEmpagliflozin | 166 | $141,986 |
| EliquisApixaban | 90 | $84,744 |
| EntrestoSacubitril/Valsartan | 56 | $61,982 |
| XareltoRivaroxaban | 21 | $24,682 |
| FarxigaDapagliflozin Propanediol | 14 | $10,486 |
| Midodrine Hcl | 43 | $3,300 |
| Torsemide | 136 | $3,109 |
| Metoprolol Succinate | 116 | $1,900 |
| Potassium Chloride | 82 | $1,654 |
| Eplerenone | 28 | $1,355 |
| Losartan Potassium | 61 | $822 |
| Atorvastatin Calcium | 77 | $813 |
| Spironolactone | 118 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $68 | $5,612,603343 claims |
| Boehringer IngelheimJardiance | $26 | $141,986166 claims |
| NovartisEntresto | $24 | $61,98256 claims |
| Johnson & JohnsonXarelto | $50 | $24,68221 claims |
| AstraZenecaFarxiga | $25 | $10,48614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 adult health providers in South Carolina.
Other adult health in Charleston
- Michelle PriceCharleston$13K
- Lauren DelbridgeCharleston$9K
- Lisa SmithCharleston$6K
- Natalie ObryanCharleston$4K
- Karen RobertsonGreenville$69K
- Christine FranzeseTega Cay$30K
- Jessica RiceGreenville$15K
- Melissa McCarterSpartanburg$12K
- Andrea OlsonWest Columbia$12K
- Jennifer BrittIrmo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.